BioSpace News Archive

Center For Sight, A US Eye Company, one of the nation’s leading ophthalmology practices, has performed the first iDoseTR implant surgery in the state of Florida since the device was approved by the Food and Drug Administration in December, 2023.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 18,400 shares of the Company’s common stock at an exercise price per share of $16.47, which was the closing price on March 25, 2024, and restricted stock units to acquire a total of 9,200 shares of the Company’s common stock.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH).

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present virtually at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:30 AM ET.

Biofrontera, Inc. announced that its 2024 Annual Meeting of Stockholders will be held on June 12, 2024 and that the close of business on April 22, 2024 will be the record date for the determination of stockholders entitled to notice of and to vote at the 2024 Annual Meeting.

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP) today announced fourth quarter and full-year 2023 results for the period ended December 31, 2023.

Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix’s miniature robotic-assisted gamma probe used to detect radiation in patients and guide surgery.

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Raul Torres’s Lab at the University of Colorado School of Medicine.

MediciNova, Inc. today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.

Innovent Biologics, Inc. announces that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial, for resectable MSI-H/dMMR[1] colon cancer neoadjuvant therapy.